<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02849444</url>
  </required_header>
  <id_info>
    <org_study_id>CEL-MIE-2012-01</org_study_id>
    <nct_id>NCT02849444</nct_id>
  </id_info>
  <brief_title>A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance</brief_title>
  <acronym>MIR50</acronym>
  <official_title>Post-authorisation Observational Study for the Assessment of Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance &lt;50 mL/Min/1.73 m2 (CrCl &lt;50 mL/Min/1.73 m2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multicentre, post-authorisation observational study. The objective of this&#xD;
      study is assess the response of renal function in clinical practice to anti-multiple myeloma&#xD;
      therapy in patients with relapsed MM and CrCl &lt;50 mL/min/1.73 m2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multicentre, post-authorisation observational study. Study population: Patients&#xD;
      with relapsed multiple myeloma and with CrCl &lt;50 mL/min/1.73 m2, for whom the investigator&#xD;
      decides to start a new line of anti-myeloma treatment as per normal clinical practice. The&#xD;
      decision to prescribe treatment will be clearly disassociated from the decision to include&#xD;
      the patient in the study.&#xD;
&#xD;
      300 patients are expected to be recruited (225 for Group 1 and 75 for Group 2) from 40 sites&#xD;
      (approximately 7-8 patients for each site). Patients will be included consecutively in the&#xD;
      study.&#xD;
&#xD;
      The inclusion will be stratified to ensure the presence of all stages of renal impairment&#xD;
      (RI) in two groups:&#xD;
&#xD;
      Documentation of 300 patients is planned (a maximum of 225 in group 1 and a minimum of 75 in&#xD;
      group 2) at 40 sites (approximately 7-8 patients per each site). The patients will be&#xD;
      included in the study in a consecutive manner.&#xD;
&#xD;
      In order to ensure the correct stratification of the sample group a real time central&#xD;
      registry will be kept for the patients included in each group. Once the required number of&#xD;
      patients for one of the groups is completed, inclusion in that group will be closed at all&#xD;
      sites, keeping inclusion for other groups open, and so on until the entire sample size is&#xD;
      complete.&#xD;
&#xD;
      Primary objective: To assess the response of renal function in clinical practice to&#xD;
      anti-multiple myeloma therapy in patients with relapsed MM and creatinine clearance &lt;50&#xD;
      mL/min/1.73 m2 (CrCl &lt;50 mL/min/1.73m2).&#xD;
&#xD;
      The prospective follow-up period will cover two phases:&#xD;
&#xD;
        1. Treatment phase: covers the entire time the patient is receiving the first anti-myeloma&#xD;
           treatment for relapse* for which he/she is included in this study.&#xD;
&#xD;
        2. Follow-up phase: A 36-month extension period after the end of the first anti-myeloma&#xD;
           treatment for relapse for which he/she was included in the study.&#xD;
&#xD;
             -  Any change in therapeutic regimens, for example, discontinuation or addition of a&#xD;
                drug (except for changes in dose for some of the initial drugs) will mark the end&#xD;
                of the treatment phase and the passing of the patient to the follow-up phase. In&#xD;
                case of temporary interruptions in treatment under 30 days (or of any duration if&#xD;
                the reason for interruption is toxicity) the patient will continue in the treatment&#xD;
                phase, provided that the initial treatment regimen for the relapse it resumed.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To describe the clinical and demographic characteristics of patients with relapsed&#xD;
           multiple myeloma and CrCl &lt;50 mL/min/1.73 m2.&#xD;
&#xD;
        -  To assess the response rate of renal function in clinical practice to anti-multiple&#xD;
           myeloma therapy in patients with relapsed multiple myeloma and CrCl &lt;50 mL/min/1.73 m2.&#xD;
&#xD;
        -  To assess the response of renal function based on the therapeutic regimens administered.&#xD;
&#xD;
        -  To explore the concordance of the kidney function response and that of the myeloma in&#xD;
           the clinical practice to the anti-myeloma treatment between consecutive relapses in the&#xD;
           same patient.&#xD;
&#xD;
        -  To assess time-dependent response parameters.&#xD;
&#xD;
        -  To analyse the safety of treatments administered in clinical practice.&#xD;
&#xD;
        -  To describe the use of resources associated with anti-myeloma therapy in clinical&#xD;
           practice that can be measured financially, and to explore the possible differences&#xD;
           between the various therapeutic regimens administered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2012</start_date>
  <completion_date type="Actual">December 10, 2020</completion_date>
  <primary_completion_date type="Actual">December 23, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Creatinine levels to determinates Renal function response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Creatinine records from basal visit to last visit to determinates Creatinine clearance with the Cockcroft-Gault formula.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Age of participants at baseline to determinates Renal function response</measure>
    <time_frame>Baseline visit</time_frame>
    <description>Patient Age record to determinates Creatinine clearance with the Cockcroft-Gault formula.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight of participants at baseline to determinates Renal function response</measure>
    <time_frame>Baseline visit</time_frame>
    <description>Patient weight recorded in each visit to determinates Creatinine clearance with the Cockcroft-Gault formula.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gender of participants at baseline to determinates Renal function response</measure>
    <time_frame>Baseline visit</time_frame>
    <description>Patient gender recorded in basal visit to determinates Creatinine clearance with the Cockcroft-Gault formula.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Race of participants at Baseline</measure>
    <time_frame>Baseline visit</time_frame>
    <description>To describe the demographic characteristics of patients with relapsed multiple myeloma and CrCl &lt;50 mL/min/1.73 m2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome of participants with Multiple Myeloma (MM) clinical description</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To describe the clinical characteristics of patients with relapsed multiple myeloma and CrCl &lt;50 mL/min/1.73 m2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal response rate assessment in clinical practice.</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Describe response rate of renal function according to eGFR and total proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time dependent Renal response rate assessment in clinical practice.</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Time to best renal response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of Anti-myeloma therapeutic regimens.</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Describe various types of anti-myeloma regimens participants will receive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Myeloma (MM) response to anti-myeloma treatment</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>MM response evaluation according to IMWG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MM response to Time to Progression</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Time to progression is defined as time from baseline to the appearance of the event; considering as an event progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MM response to Time to first response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Time to response is defined as time from the date of the first dose of study treatment to the date of the first documented hematologic improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MM response to Progression Free Survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Progression free survival is defined as time from the date of the first dose of study treatment to the date of the first documented disease progression or relapse per IWG 2006 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of visit to hospital/primary health care associated with anti-myeloma therapy</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To describe the costs associated with anti-myeloma therapy in clinical practice that can be measured financially, and to explore the possible differences between the various therapeutic regimens administered. This includes, visits to hospital/primary health care center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with relapsed kidney function</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Concordance of the kidney function response and that of the myeloma in the clinical practice to the anti-myeloma treatment between consecutive relapses in the same patient.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">326</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Moderate kidney failure</arm_group_label>
    <description>30 ≤ CrCl &lt; 50 mL/min/1.73 m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe kidney failure</arm_group_label>
    <description>CrCl &lt; 30 mL/min/1.73 m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anti-myeloma treatment at physician discretion</intervention_name>
    <description>non Interventional Study</description>
    <arm_group_label>Moderate kidney failure</arm_group_label>
    <arm_group_label>Severe kidney failure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with relapsed /refractorymultiple myeloma and with CrCl &lt;50 mL/min/1.73 m2, for&#xD;
        whom the investigator decides to start a new line of anti-myeloma treatment as per normal&#xD;
        clinical practice. The decision to prescribe treatment will be clearly disassociated from&#xD;
        the decision to include the patient in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of both genders, aged equal or more than 18 years.&#xD;
&#xD;
          2. Patients with documented relapsed multiple myeloma according to International Myeloma&#xD;
             Working Group ( IMWG) criteria.&#xD;
&#xD;
          3. Patients with documented renal damage defined as creatinine clearance &lt;50 ml / min /&#xD;
             1.73 m2 (CrCl &lt;50ml / min / 1.73m2).&#xD;
&#xD;
          4. Patients to whom the researcher decides to initiate anti-myeloma treatment for relapse&#xD;
             with one or more agents according to clinical practice *.&#xD;
&#xD;
          5. Patients who consent in writing after it has been clearly explained to them the nature&#xD;
             and purpose of the study (written informed consent).&#xD;
&#xD;
          6. Subject with any of the following characteristics (at least one of the 2 following&#xD;
             options must be Yes):&#xD;
&#xD;
               -  Subjects who have not previously participated in the study&#xD;
&#xD;
               -  Subjects who have previously participated in the study, who meet all the&#xD;
                  inclusion criteria again and to whom none of the exclusion criteria apply, and&#xD;
                  whose current relapse is consecutive to the relapse that prompted their initial&#xD;
                  inclusion in the study.&#xD;
&#xD;
                    -  The decision to prescribe treatment will be clearly dissociated from the&#xD;
                       decision to include the patient in the study&#xD;
&#xD;
                         -  Clarification is provided as to the aim of the study, which is to&#xD;
                            encompass all relapse subcategories included in the International&#xD;
                            Myeloma Working Group consensus document published in 2006. Therefore,&#xD;
                            all patients with clinically relapsed multiple myeloma, who are in&#xD;
                            relapse following a complete response or in progression (including&#xD;
                            refractory cases) as defined in point 8.1 and in table 4 of the&#xD;
                            protocol, are considered eligible candidates for participation in the&#xD;
                            EPA-MIR 50 study, as long as they meet all the other criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are participating in an interventional clinical trial * or who refuse to&#xD;
             participate in the study.&#xD;
&#xD;
          2. Patients with CrCl &lt;50 ml / min / 1.73m2 due to a cause other than multiple myeloma&#xD;
             properly documented at the discretion of the investigator *.&#xD;
&#xD;
               -  The inclusion of patients who are participating in another observational study is&#xD;
                  permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mireya Navarro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Ciudad de Jaen</name>
      <address>
        <city>Jaen</city>
        <state>Andalucia</state>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Torrecárdenas</name>
      <address>
        <city>Almería</city>
        <state>Andalucía</state>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>Cádiz</city>
        <state>Andalucía</state>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Nieves</name>
      <address>
        <city>Granada</city>
        <state>Andalucía</state>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital general de jeréz</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Andalucía</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la macarena</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cabueñes</name>
      <address>
        <city>Gijón</city>
        <state>Asturias</state>
        <zip>33394</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Insular de Gran Canaria</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Canarias</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <state>Castilla La Mancha</state>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Castilla Y León</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Burgos</name>
      <address>
        <city>Burgos</city>
        <state>Castilla Y León</state>
        <zip>09007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de León</name>
      <address>
        <city>León</city>
        <state>Castilla Y León</state>
        <zip>24001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rio Hortega de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <state>Castilla Y León</state>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Ribera</name>
      <address>
        <city>Alzira</city>
        <state>Cataluña</state>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Duran reynls</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Josep Trueta de Girona</name>
      <address>
        <city>Girona</city>
        <state>Cataluña</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <state>Cataluña</state>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de manresa</name>
      <address>
        <city>Manresa</city>
        <state>Cataluña</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sabadell ( Parc Taulí)</name>
      <address>
        <city>Sabadell</city>
        <state>Cataluña</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Cataluña</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Valencia</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Galicia</state>
        <zip>36036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital san pedro</name>
      <address>
        <city>Logroño</city>
        <state>La Rioja</state>
        <zip>26006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fundación de Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Lucía</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <zip>30202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de Arrixaca</name>
      <address>
        <city>El Palmar, Murcia</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <state>Valencia</state>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Universitario de San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal function</keyword>
  <keyword>Relapsed Multiple myeloma</keyword>
  <keyword>anti-MM therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

